Merck stops trials of blood cancer drug after risk assessment

By Reuters News

- Merck MRK.N said on Tuesday it would stop development of its experimental blood cancer drug, nemtabrutinib, after a review found the treatment's benefits may not outweigh its risks.

An independent monitoring committee reached that conclusion after reviewing results from a late-stage study of the drug. Merck said its review of the full data confirmed the finding.

The drugmaker did not disclose what risks were found. It did not immediately respond to a Reuters request for comment.

The company will also discontinue two other late-stage trials of the drug. The oral drug was being evaluated for chronic lymphocytic leukemia and other blood cancers.

The analyses are ongoing and the results will be shared with the scientific community, it said.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.